Hematospermia and Cloacogenic Transitional Cell Carcinoma: A Twist on Significance and Meaning

1. Introduction

Hematospermia, the presence of blood in the ejaculate, is generally considered benign. There are multiple possible etiologies ranging from inflammation and infection to structural abnormalities [1–7]. Only in about 2% of cases is hematospermia associated with malignancy of the genitourinary tract [1]. We present a patient initially referred for complaint of recurrent hematospermia who, on further evaluation, was found to have a transitional cell carcinoma of the rectum. While transitional cell carcinoma (TCC) is a common genitourinary cancer, its presence in the anus and rectum is rare, accounting for 2%-3% of anorectal cancers [8]. This case is a remarkable example of two pathologic processes presenting in rare form and underscores the value of a thorough investigation of hematospermia when associated with other clinical symptoms.

2. Case Report

A 52-year-old man presented with a 6-week history of hematospermia, describing his ejaculate as brown in color. There was no history of trauma, and the patient denied any hematuria. On further questioning he reported a 3-month history of constipation and difficulty voiding. Rectal examination revealed a firm, polypoid mass and colonoscopy showed suspicious, ulcerated lesions of the rectal mucosa with narrowing of the rectal vault. Pathology demonstrated transitional cell carcinoma of the rectum. While transitional cell carcinoma is a common genitourinary cancer, its presence in the anus and rectum is exceedingly rare. Furthermore, hematospermia is generally not associated with malignancy. This case is a remarkable example of two pathologic processes presenting in rare form and underscores the value of a thorough investigation of hematospermia when associated with other clinical symptoms.
junction and pathology was consistent with high-grade TCC of the colonic epithelium (Figure 2). There was question of primary colonic TCC versus primary bladder carcinoma with secondary colonic involvement; however cystoscopy revealed normal anatomy and no evidence of primary bladder neoplasm.

With the most likely diagnosis of transitional cell cloacogenic carcinoma of the anorectal verge, the patient underwent treatment with gemcitabine and cisplatin administered every 21 days, similar to the traditional treatment for TCC of the bladder [9–12]. Restaging studies showed tumor regression and no development of metastatic disease. He is currently receiving 5-fluorouracil and mitomycin concomitant with radiation therapy given effectiveness in TCC [13].

3. Discussion

Hematospermia, while worrisome and distressing to patients, almost always represents a benign condition. The average age at presentation is 37, and it is seen in approximately 1:5,000 new patients presenting to a urology clinic [2]. However, it is
Inflammation or infection accounts for 39%–55% of cases [3]. Only in very rare cases has hematospermia been seen in conjunction with malignancy. In most instances hematospermia is iatrogenic. The most common etiology is prostate biopsy, with hematospermia seen in 50–80% of men undergoing this procedure [4, 5]. Outside of biopsy, iatrogenic causes include external beam radiation therapy, brachytherapy, and vasectomy [7]. Inflammatory processes associated with hematospermia include perineal or pelvic trauma (i.e., repetitive injury such as cycling or chronic constipation) and calculi of the seminal vesicles, prostate, urethra, bladder, and ureters. Prolonged sexual abstinence has also been associated with hematospermia, as the expulsion of semen from a distended seminal vesicle can lead to mucosal irritation and bleeding [3]. Conversely, vigorous sexual intercourse or masturbation can lead to genital congestion and bleeding [6]. Finally, infections leading to prostatitis, urethritis, orchitis, epididymitis, and spermatocystitis also induce mucosal inflammation, leading to hematospermia. These cases are often associated with irritative genitourinary symptoms or pain [6].

Hematospermia has also been associated with systemic illnesses, such as hypertension, coagulation disorders, scurvy, amyloidosis, and cirrhosis. Vascular disorders such as prostatic varices or telangiectasias, urethral hemangioma, and AV malformations can also lead to hematospermia [6, 7]. Structural abnormalities leading to hematospermia include prostatic, seminal vesicle and ejaculatory duct cysts, ejaculatory duct obstruction, and urethral stricture.

Evidence of association with malignancy is scarce and often limited to case reports or case series. Such cases have included primary seminal vesicle adenocarcinoma [14], metastatic melanoma to the seminal vesicle [15], primary testicular cancer [16], and primary prostate cancer [17]. One retrospective analysis of 26,126 men of ages 50 and older demonstrated 19 cases of cancer in the 139 men who presented with hematospermia (13.7% incidence) versus 6.5% of cancer cases seen in men without hematospermia [18].

However, one literature review found only 33 tumors, 25 of them prostatic, among 931 cases of hematospermia—an incidence of 3.5% [7]. Similarly, a case series of 300 men with hematospermia showed only a 5.7% incidence of prostate cancer during long-term follow-up [19]. Virtually all cases of hematospermia associated with cancer are seen in men older than age of 40 years [6]. This is the first reported case of hematospermia as the presenting manifestation of anorectal carcinoma.

As most cases tend to be benign in origin, diagnostic workup is often minimal and catered to the individual patient. Some physicians recommend more thorough evaluation for hematospermia in men over age of 40, as there is higher likelihood of detecting a more serious disease entity [7]. Blood pressure should be evaluated. Thorough palpation and examination of penis, testes, epididymides, vasa deferentia, and urethra should be undertaken to evaluate for any structural abnormalities or suspicious lesions. Rectal examination allows for evaluation of the prostate—tenderness may suggest infection or inflammation, while nodularity or firmness could indicate a neoplasm. Concern for neoplasm may also warrant prostate specific antigen (PSA) testing as well as radiographic imaging. Transrectal ultrasonography (TRUS) can also allow for visualization of calculi, cysts, mullerian duct remnants, prostatic varices, and inflammatory changes. This may be a particularly useful imaging modality in men with chronic hematospermia [20, 21]. Urinalysis can rule out hematuria or infection.

Management is typically expectant, as the majority of cases will self-resolve. Underlying causes should be treated appropriately. Infections can be managed with appropriate antimicrobials, cysts of the prostate or seminal vesicle can be aspirated under TRUS guidance, and ductal obstructions may be resected transurethrally [6, 22].

TCC is a malignancy most commonly seen in the urogenital tract, where it is termed urothelial carcinoma. However, some cases of anorectal cancer are also of transitional cell origin and in this context are often referred to as “cloacogenic” or “basaloid” carcinoma. These rare tumors account for 2%-3% of all anorectal carcinomas and occur 1.5–2 times as often in females. The average patient age is 60 [8, 23, 24]. Some suggested etiologies include Crohn’s disease, anal intercourse, and chronic fistula-in-ano. However, the patient presented in this case had no predisposing factors. Presenting symptoms are similar to those of other anorectal neoplasms and may include hematochezia, rectal pain, change in bowel habits, or anal mass [25].

The onset of symptoms is often abrupt, with the duration of symptoms for cloacogenic carcinoma being generally shorter in comparison to those for squamous cell anal neoplasms [25]. The patient described in this report had a normal colonoscopy two years prior to onset of symptoms. One study showed lymph node metastases at time of surgery in one-third of cases, and extranodal metastases in 19% of cases [24].

Cloacogenic carcinomas typically originate around the pectinate line of the anal canal, where the simple columnar epithelium of the upper third meets the stratified squamous epithelium of the lower two-thirds. At this junction, the columnar epithelium becomes cuboidal and gradually changes into transitional epithelium, extending to cover the anal valves just proximal to the pectinate line. The transitional epithelium of the urogenital aspect of the cloaca can be retained in the anal glands at the border of the pectinate line, thus explaining the presence of transitional epithelium in the anal canal [8, 26].

Anorectal TCC is sometimes considered a subset of anorectal squamous cell carcinoma (SCC) [27]. Due to its rarity, there is little research devoted specifically to the management of anorectal TCC. As such, treatment modalities have typically been based upon the Nigro protocol, which has been a long-held gold standard for anal SCC. This consists of 5-fluorouracil (5-FU), mitomycin (MMC), and radiation therapy [27, 28]. This protocol has also been demonstrated to improve control and survival rates of bladder TCC [13]. One small study of anal cloacogenic carcinoma found that 5-FU plus MMC or cisplatin led to three- and five-year survival rates of 71% and 48%, respectively [25]. Other studies have considered the addition of cisplatin to this regimen, with and without radiation, although they failed to show any
superiority to the Nigro protocol for treatment of anal SCC [29]. Systemic gemcitabine in combination with cisplatin is considered a standard first-line regimen for patients with advanced TCC of the bladder [9–11].

4. Conclusions

This case is the first description of hematospermia due to invasive anorectal carcinoma and is instructive for the clinical assessment of patients presenting with hematospermia, although rare, regional, invasive disease originating outside the urinary tract may cause unusual presentations. It also reminds the clinician that TCC does not always arise from the urothelium and may manifest from the anorectal verge. As hematospermia is often considered benign and self-resolving, this case underscores the importance of investigation and workup when associated with other clinical symptoms.

Conflict of Interests

All authors declare no conflict of interests.

References

[1] J. E. Mulhall and P. C. Albertsen, “Hemospermia: diagnosis and management,” Urology, vol. 46, no. 4, pp. 463–467, 1995.
[2] W. Akhter, F. Khan, and F. Chinegwundoh, “Should every patient with hematospermia be investigated? A critical review,” Central European Journal of Urology, vol. 66, no. 1, pp. 79–82, 2013.
[3] V. Klevecka, A. Jatulis, V. Kraniauskas, V. Salkauskas, A. Ukosas, and P. Zeromskas, “Hemospermia,” Medicina, vol. 41, no. 4, pp. 359–364, 2005.
[4] R. Raaijmakers, W. J. Kirkels, M. J. Roobol, M. F. Wildhagen, and F. H. Schruder, “Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program,” Urology, vol. 60, no. 5, pp. 826–830, 2002.
[5] M. Manoharan, R. Ayyathurai, A. M. Nieder, and M. S. Soloway, “Hemospermia following transrectal ultrasound-guided prostate biopsy: a prospective study,” Prostate Cancer and Prostatic Diseases, vol. 10, no. 3, pp. 283–287, 2007.
[6] P. Kumar, S. Kapoor, and V. Nargund, “Haemospermia—a systematic review,” Annals of the Royal College of Surgeons of England, vol. 88, no. 4, pp. 339–342, 2006.
[7] I. Ahmad and N. S. Krishna, “Hemospermia,” The Journal of Urology, vol. 177, no. 5, pp. 1613–1618, 2007.
[8] J. D. Sink, S. A. Kramer, D. D. Copeland, and H. F. Seigler, “Cloacogenic carcinoma,” Annals of Surgery, vol. 188, no. 1, pp. 53–59, 1978.
[9] H. Von der Maase, L. Sengelov, J. T. Roberts et al., “Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer,” Journal of Clinical Oncology, vol. 23, no. 21, pp. 4602–4608, 2005.
[10] A. Dash, J. Pettus, H. Herr et al., “A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder,” Cancer, vol. 113, no. 9, pp. 2471–2477, 2008.
[11] J. T. Roberts, H. von der Maase, L. Sengelov et al., “Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer,” Annals of Oncology, vol. 17, supplement 5, pp. v118–v122, 2006.
[12] H. Von der Maase, S. W. Hansen, J. T. Roberts et al., “Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study,” Journal of Clinical Oncology, vol. 18, no. 17, pp. 3068–3077, 2000.
[13] N. D. James, S. A. Hussain, E. Hall et al., “Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer,” The New England Journal of Medicine, vol. 366, no. 16, pp. 1477–1488, 2012.
[14] A. Eken, V. Izol, I. A. Aridogan, S. Erdogan, A. Acikalin, and Z. Tansug, “An unusual cause of hemospermia: primary adenocarcinoma of the seminal vesicle,” Journal of the Canadian Urological Association, vol. 6, no. 6, pp. E259–E262, 2012.
[15] M. V. Meng and L. H. Werboff, “Hemospermia as the presenting symptom of metastatic malignant melanoma of unknown primary origin,” Urology, vol. 56, no. 2, p. 330, 2000.
[16] P. Maheshkumar, U. Otto, S. Gordon, D. M. Berney, and V. H. Nargund, “Testicular tumor presenting as hemospermia,” The Journal of Urology, vol. 165, no. 1, p. 188, 2001.
[17] D. M. Rubinowicz, M. S. Soloway, M. Lief, and F. Civantos, “Hemospermia and expressed tumor in the urethra: an unusual presentation of ductal carcinoma of the prostate,” The Journal of Urology, vol. 163, no. 3, article 915, 2000.
[18] M. Han, R. E. Brannigan, J. A. V. Antenor, K. A. Roehl, and W. J. Catalona, “Association of hemospermia with prostate cancer,” Journal of Urology, vol. 172, no. 6, part 1, pp. 2189–2192, 2004.
[19] Y. H. Ng, J. P. Seeley, and G. Smith, “Haematospermia as a presenting symptom: outcomes of investigation in 300 men,” Surgeon, vol. 11, no. 1, pp. 35–38, 2013.
[20] J. H. Worischeck and R. O. Parra, “Chronic hematospermia: assessment by transrectal ultrasound,” Urology, vol. 43, no. 4, pp. 515–520, 1994.
[21] H. Zhao, J. Luo, D. Wang et al., “The value of transrectal ultrasound in the diagnosis of hemospermia in a large cohort of patients,” Journal of Andrology, vol. 33, no. 5, pp. 897–903, 2012.
[22] K. B. Stefanovic, P. C. Gregg, and M. Soung, “Evaluation and treatment of hemospermia,” American Family Physician, vol. 80, no. 12, pp. 1421–1427, 2009.
[23] R. G. Klotz Jr., T. Pamukcoglu, and D. H. Souilliard, “Transitional cloacogenic carcinoma of the anal canal. Clinicopathologic study of three hundred seventy-three cases,” Cancer, vol. 80, no. 10, pp. 1727–1745, 1997.
[24] L. E. Scott and L. J. Bernard, “Transitional cloacogenic carcinoma of the anus and rectum: report of three cases,” Journal of the National Medical Association, vol. 71, no. 5, pp. 493–494, 1979.
[25] E. Bertani, A. Chiappa, G. Mazzarol et al., “Aggressive treatment approach for cloacogenic carcinoma of the anorectum: report from a single cancer center,” Digestive Surgery, vol. 27, no. 4, pp. 297–301, 2010.
[26] L. Grodsky, “Current concepts on cloacogenic transitional cell anorectal cancers,” The Journal of the American Medical Association, vol. 207, no. 11, pp. 2057–2061, 1969.
[27] J. V. Klas, D. A. Rothenberger, W. D. Wong, and R. D. Madoff, “Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes,” Cancer, vol. 85, no. 8, pp. 1686–1693, 1999.

[28] N. D. Nigro, V. K. Vaitkevicius, and B. Considine Jr., “Combined therapy for cancer of the anal canal: a preliminary report,” Diseases of the Colon and Rectum, vol. 17, no. 3, pp. 354–356, 1974.

[29] A. Abbas, G. Yang, and M. Fakih, “Management of anal cancer in 2010. Part 2: current treatment standards and future directions,” Oncology, vol. 24, no. 5, pp. 417–424, 2010.